Overview
SCIENTIFIC SCORE
Questionable
Based on 16 Researches
6.4
USERS' SCORE
Good
Based on 8 Reviews
8.3
Supplement Facts
Serving Size: 2 Tablets
Amount Per Serving
%DV
Magnesium (from 2,000 mg magnesiumlysinate glycinate chelate) (Albion®)
200 mg
48%
Top Medical Research Studies
7
Magnesium supplementation reduces atrial fibrillation
We wanted to understand the effectiveness of magnesium supplementation in preventing atrial fibrillation, a common heart rhythm issue in critical care patients. In our study, we looked at patient data from a single center, analyzing the varied practices of bedside nurses regarding magnesium treatment.
By examining the approach of individual nurses, we identified two groups: those who tended to be liberal with magnesium administration and those who were more restrictive. Through rigorous analysis, we found that magnesium supplementation was linked to a 3% decrease in the relative risk of developing atrial fibrillation. This suggests that implementing routine magnesium treatment could be beneficial for patients.
While our findings support the idea of using magnesium to help prevent atrial fibrillation, we recognize that more research is needed to determine the best serum magnesium levels for maximum benefit. Overall, our study offers promising insights into how magnesium can play a role in improving patient care in critical settings.
By examining the approach of individual nurses, we identified two groups: those who tended to be liberal with magnesium administration and those who were more restrictive. Through rigorous analysis, we found that magnesium supplementation was linked to a 3% decrease in the relative risk of developing atrial fibrillation. This suggests that implementing routine magnesium treatment could be beneficial for patients.
While our findings support the idea of using magnesium to help prevent atrial fibrillation, we recognize that more research is needed to determine the best serum magnesium levels for maximum benefit. Overall, our study offers promising insights into how magnesium can play a role in improving patient care in critical settings.
Read More
9
Magnesium may reduce postoperative AF
We explored the impact of magnesium sulfate (MgS) on the occurrence of postoperative atrial fibrillation (POAF) in patients undergoing lung surgery via thoracotomy. In a prospective observational study involving 100 patients, we looked at how adding MgS to standard anesthetic management affected the rates of AF after surgery. MgS was given during anesthesia induction and through an infusion over 24 hours to assess its potential benefits.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
Read More
8
We explored the connection between serum magnesium levels and major cardiovascular events among patients with atrial fibrillation (AF). The study involved 413 participants with AF, all of whom had their magnesium levels measured during a specific visit in the ARIC Study. Over an average follow-up of about 5.8 years, we monitored key health events such as heart failure, heart attacks, strokes, and overall mortality.
Our findings highlighted that higher serum magnesium levels were associated with a reduced risk of experiencing a heart attack. Specifically, participants in the highest magnesium group had an impressive 80% lower rate of heart attacks compared to those in the lowest group. While the improvements in other health outcomes were noted, they were not as striking, making it clear that the strongest benefit of magnesium focused primarily on heart attack risk.
Although we didn't find strong associations with every health endpoint studied, the evidence suggests that managing magnesium levels could play a beneficial role for those with atrial fibrillation. However, more research with larger cohorts is necessary to fully understand how magnesium might help in preventing adverse cardiovascular outcomes in these patients.
Our findings highlighted that higher serum magnesium levels were associated with a reduced risk of experiencing a heart attack. Specifically, participants in the highest magnesium group had an impressive 80% lower rate of heart attacks compared to those in the lowest group. While the improvements in other health outcomes were noted, they were not as striking, making it clear that the strongest benefit of magnesium focused primarily on heart attack risk.
Although we didn't find strong associations with every health endpoint studied, the evidence suggests that managing magnesium levels could play a beneficial role for those with atrial fibrillation. However, more research with larger cohorts is necessary to fully understand how magnesium might help in preventing adverse cardiovascular outcomes in these patients.
Read More
Most Useful Reviews
9
Successful magnesium treatment
18 people found this helpful
I've suffered from atrial fibrillation for about five years and have tried numerous medications that affected my thyroid. Despite having RFA, I still felt interruptions in my heart. A cardiologist suggested magnesium, leading me to Doctor's Best. After taking it for three weeks, I've enjoyed sinus rhythm for over ten days without seizures, even after stress! I suspect my arrhythmia was due to magnesium deficiency.
Read More
9
Improved heart rhythm
4 people found this helpful
I have successfully supplemented with Doctor's Best to manage my atrial fibrillation. It has undoubtedly contributed to my long stretch without arrhythmia. Doctor's Best is the most reliable glycinated product I’ve discovered, and I highly recommend it for heart rhythm supplementation.
Read More
9
No more relapses
I've been using these for my atrial fibrillation for over two years, noticing a gradual reduction in episodes. I haven't had a relapse for more than a year and believe these magnesium tablets have contributed to my improvement. However, it’s crucial for others to consult a doctor for advice on their cases.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 16 Researches
6.4
- All Researches
9
Magnesium may reduce postoperative AF
We explored the impact of magnesium sulfate (MgS) on the occurrence of postoperative atrial fibrillation (POAF) in patients undergoing lung surgery via thoracotomy. In a prospective observational study involving 100 patients, we looked at how adding MgS to standard anesthetic management affected the rates of AF after surgery. MgS was given during anesthesia induction and through an infusion over 24 hours to assess its potential benefits.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
While we found no significant impact on the first three days after surgery, by day seven, patients who received MgS showed a marked reduction in POAF compared to those who did not receive it. Specifically, the rates were 4% for the MgS group compared to 26% for the control group. Notably, in patients who were not on long-term beta-blockers, the benefits were even clearer, with only 14% experiencing AF compared to 80% in the control group.
Overall, our findings suggest that using magnesium sulfate may be a valuable strategy for lowering the risk of POAF, particularly for patients not already taking beta-blockers. This treatment approach could lead to smoother recoveries, shorter hospital stays, and potentially lower healthcare costs.
Read More
8
Magnesium's uncertain impact on AF
We investigated the role of magnesium among various treatments for atrial fibrillation (AF) in a comprehensive study reviewing multiple clinical trials. The analysis highlighted the effectiveness of both electrical and pharmacological cardioversion methods.
Magnesium was included in this analysis alongside other treatments like ibutilide and propafenone. However, the evidence for magnesium's specific impact on maintaining sinus rhythm was deemed low-certainty and not entirely definitive. We observed that while magnesium may show some promise, its effects were not as clearly established compared to the more robust outcomes seen with other medications.
Despite these findings, our study emphasizes the significance of patient profiles and treatment options available for managing AF. Although magnesium treatment is part of the conversation on atrial fibrillation management, its distinct benefits remain somewhat unclear when compared to other cardioversion methods.
Magnesium was included in this analysis alongside other treatments like ibutilide and propafenone. However, the evidence for magnesium's specific impact on maintaining sinus rhythm was deemed low-certainty and not entirely definitive. We observed that while magnesium may show some promise, its effects were not as clearly established compared to the more robust outcomes seen with other medications.
Despite these findings, our study emphasizes the significance of patient profiles and treatment options available for managing AF. Although magnesium treatment is part of the conversation on atrial fibrillation management, its distinct benefits remain somewhat unclear when compared to other cardioversion methods.
Read More
8
We conducted a nationwide study focusing on how serum magnesium (sMg) levels are linked to atrial fibrillation (AF) in patients undergoing hemodialysis. By analyzing data from 165,926 patients across 2,549 dialysis facilities in Japan, we aimed to assess if variations in magnesium levels truly influenced the occurrence of AF.
Our findings revealed that lower sMg levels could lead to a higher risk of AF. Specifically, patients with sMg levels less than 2.5 mg/dL showed increased odds of AF compared to those within the optimal range. Interestingly, those with sMg levels above this range had fewer cases of AF. This suggests that maintaining appropriate magnesium levels could be essential for heart rhythm stability.
However, we noted that while dysmagnesemia appears to contribute to AF in this population, there is still a need for further research. Longitudinal studies are necessary to truly determine if correcting magnesium levels can reduce AF incidence effectively. Ultimately, the connection between magnesium and atrial fibrillation is a complex one, and this study adds valuable insights to a growing body of evidence.
Our findings revealed that lower sMg levels could lead to a higher risk of AF. Specifically, patients with sMg levels less than 2.5 mg/dL showed increased odds of AF compared to those within the optimal range. Interestingly, those with sMg levels above this range had fewer cases of AF. This suggests that maintaining appropriate magnesium levels could be essential for heart rhythm stability.
However, we noted that while dysmagnesemia appears to contribute to AF in this population, there is still a need for further research. Longitudinal studies are necessary to truly determine if correcting magnesium levels can reduce AF incidence effectively. Ultimately, the connection between magnesium and atrial fibrillation is a complex one, and this study adds valuable insights to a growing body of evidence.
Read More
8
We explored the effects of magnesium treatment in patients with atrial fibrillation (AF) undergoing cardioversion with ibutilide. In our study, patients were carefully monitored; those with low magnesium levels received magnesium sulfate before ibutilide was administered.
The results showed that magnesium pretreatment improved patients' chances of converting back to a normal heart rhythm. Specifically, those who received magnesium saw a 70% success rate in returning to normal sinus rhythm (NSR).
We also noticed a significant gender difference in conversion rates—female patients converted to NSR at an impressive rate of 88%, compared to just 68% for males. This finding was interesting and may suggest that factors beyond magnesium alone contribute to treatment success in AF.
The results showed that magnesium pretreatment improved patients' chances of converting back to a normal heart rhythm. Specifically, those who received magnesium saw a 70% success rate in returning to normal sinus rhythm (NSR).
We also noticed a significant gender difference in conversion rates—female patients converted to NSR at an impressive rate of 88%, compared to just 68% for males. This finding was interesting and may suggest that factors beyond magnesium alone contribute to treatment success in AF.
Read More
8
Magnesium aids atrial fibrillation control
We evaluated the impact of intravenous magnesium (IV Mg) on patients experiencing atrial fibrillation (AF) with a rapid heartbeat. Our study involved a systematic review and meta-analysis of randomized controlled trials, comparing the effects of IV Mg to a placebo while patients received standard care.
Our analysis included nine trials with over a thousand patients. Remarkably, we found that IV Mg not only helped achieve better control over heart rate but also improved the chances of reverting to a normal rhythm. Specifically, it increased rate control by 87% and rhythm control by 45%, making it a promising addition to existing treatments.
We also noted that patients tolerated IV Mg well, and while side effects weren't reported in detail, there was no significant difference between groups regarding their occurrence. This suggests that magnesium could be a beneficial adjunct therapy for managing AF, especially for those who are not post-operative.
Our analysis included nine trials with over a thousand patients. Remarkably, we found that IV Mg not only helped achieve better control over heart rate but also improved the chances of reverting to a normal rhythm. Specifically, it increased rate control by 87% and rhythm control by 45%, making it a promising addition to existing treatments.
We also noted that patients tolerated IV Mg well, and while side effects weren't reported in detail, there was no significant difference between groups regarding their occurrence. This suggests that magnesium could be a beneficial adjunct therapy for managing AF, especially for those who are not post-operative.
Read More
User Reviews
USERS' SCORE
Good
Based on 8 Reviews
8.3
- All Reviews
- Positive Reviews
- Negative Reviews
9
Successful magnesium treatment
18 people found this helpful
I've suffered from atrial fibrillation for about five years and have tried numerous medications that affected my thyroid. Despite having RFA, I still felt interruptions in my heart. A cardiologist suggested magnesium, leading me to Doctor's Best. After taking it for three weeks, I've enjoyed sinus rhythm for over ten days without seizures, even after stress! I suspect my arrhythmia was due to magnesium deficiency.
Read More
9
Improved heart rhythm
4 people found this helpful
I have successfully supplemented with Doctor's Best to manage my atrial fibrillation. It has undoubtedly contributed to my long stretch without arrhythmia. Doctor's Best is the most reliable glycinated product I’ve discovered, and I highly recommend it for heart rhythm supplementation.
Read More
9
No more relapses
I've been using these for my atrial fibrillation for over two years, noticing a gradual reduction in episodes. I haven't had a relapse for more than a year and believe these magnesium tablets have contributed to my improvement. However, it’s crucial for others to consult a doctor for advice on their cases.
Read More
7.5
Positive results
1 people found this helpful
After considerable online research on CHF and atrial fibrillation for my husband, we started taking Magnesium seven months ago. Both of us have experienced positive results; my husband saw fewer headaches and cramps. Last month, we also began taking CoQ10 along with d-ribose and l-carnitine. I feel exceptionally fit, which I attribute to these supplements.
Read More
7.5
Improved Afib condition
Since starting these magnesium supplements over a year ago, my situation with atrial fibrillation has improved significantly, with fewer relapses. The tablets are large, so some might need to break them for easier swallowing. Overall, I would recommend them based on Labdoor’s purity and potency ratings.
Read More
Frequently Asked Questions
9
Successful magnesium treatment
18 people found this helpful
I've suffered from atrial fibrillation for about five years and have tried numerous medications that affected my thyroid. Despite having RFA, I still felt interruptions in my heart. A cardiologist suggested magnesium, leading me to Doctor's Best. After taking it for three weeks, I've enjoyed sinus rhythm for over ten days without seizures, even after stress! I suspect my arrhythmia was due to magnesium deficiency.
9
No more relapses
I've been using these for my atrial fibrillation for over two years, noticing a gradual reduction in episodes. I haven't had a relapse for more than a year and believe these magnesium tablets have contributed to my improvement. However, it’s crucial for others to consult a doctor for advice on their cases.
7.5
Improved Afib condition
Since starting these magnesium supplements over a year ago, my situation with atrial fibrillation has improved significantly, with fewer relapses. The tablets are large, so some might need to break them for easier swallowing. Overall, I would recommend them based on Labdoor’s purity and potency ratings.
6
Peaceful sleep
This quality magnesium is for my parents aged 60+ with leg cramps, offering them noticeable relief. My mother takes it regularly for heart problems and reports fewer attacks of atrial fibrillation and more tranquil sleep. Two capsules at night are essential for stress relief and anxiety.
9
Improved heart rhythm
4 people found this helpful
I have successfully supplemented with Doctor's Best to manage my atrial fibrillation. It has undoubtedly contributed to my long stretch without arrhythmia. Doctor's Best is the most reliable glycinated product I’ve discovered, and I highly recommend it for heart rhythm supplementation.
6
Better sleep quality
My arrhythmologist prescribed magnesium for my atrial fibrillation, which I now take regularly. I consume two large capsules each morning and evening. Although swallowing them is a challenge, they have improved my wellbeing and resulted in better sleep.
We conducted a clinical trial to explore whether magnesium sulphate can help prevent postoperative atrial fibrillation (POAF) in patients undergoing cardiac surgery. This phase 2 study involved 530 participants who were randomly assigned to receive either intravenous magnesium or a placebo, with the goal of keeping their magnesium levels balanced.
Our primary focus was on whether this treatment could reduce the onset of POAF in the week following surgery. Hypomagnesaemia, or low magnesium levels, is common after such procedures, and previous evidence suggested that restoring these levels might help.
By comparing outcomes between the magnesium and placebo groups, we aimed to provide clear insights into the potential benefits of magnesium in cardiac surgery. The hope is that this research could lead to better prevention strategies for POAF, ultimately improving patient outcomes after surgery.
Our primary focus was on whether this treatment could reduce the onset of POAF in the week following surgery. Hypomagnesaemia, or low magnesium levels, is common after such procedures, and previous evidence suggested that restoring these levels might help.
By comparing outcomes between the magnesium and placebo groups, we aimed to provide clear insights into the potential benefits of magnesium in cardiac surgery. The hope is that this research could lead to better prevention strategies for POAF, ultimately improving patient outcomes after surgery.
7
We explored the impact of magnesium sulfate (MgS) on patients with atrial fibrillation (AF) by analyzing data from a comprehensive study involving over 9,400 individuals in critical care settings. The study focused on various treatment strategies for AF, comparing options like beta blockers, potassium channel blockers, calcium channel blockers, and magnesium sulfate.
Our findings indicated that while magnesium showed promise in some contexts, it did not emerge as the top performer. Specifically, for controlling heart rates within certain patient groups, magnesium's effectiveness was surpassed by potassium channel blockers and calcium channel blockers. Moreover, in terms of mortality rates, magnesium did not show a distinct advantage overall.
It’s noteworthy that magnesium did not yield significant standalone benefits in achieving cardioversion, particularly when weighed against other treatment options. Instead, potassium channel blockers led to higher success in rhythm control across the patient spectrum.
Overall, our analysis reveals that while magnesium is a part of the treatment equation in atrial fibrillation, it may not be the primary player we hoped for in improving outcomes. This emphasizes the need for personalized medicine, where treatment decisions are based on individual patient characteristics and treatment responses.
Our findings indicated that while magnesium showed promise in some contexts, it did not emerge as the top performer. Specifically, for controlling heart rates within certain patient groups, magnesium's effectiveness was surpassed by potassium channel blockers and calcium channel blockers. Moreover, in terms of mortality rates, magnesium did not show a distinct advantage overall.
It’s noteworthy that magnesium did not yield significant standalone benefits in achieving cardioversion, particularly when weighed against other treatment options. Instead, potassium channel blockers led to higher success in rhythm control across the patient spectrum.
Overall, our analysis reveals that while magnesium is a part of the treatment equation in atrial fibrillation, it may not be the primary player we hoped for in improving outcomes. This emphasizes the need for personalized medicine, where treatment decisions are based on individual patient characteristics and treatment responses.
5
We set out to explore how magnesium treatment influences atrial fibrillation (AF) in critically ill patients, drawing from data collected from 1,423 ICU patients across various countries. Our study uncovered that AF affects around one in six ICU patients, often emerging in those with high disease severity or specific health conditions like hypertension.
While magnesium was administered to 16% of patients with AF, the results did not indicate significant benefits tied to its use specifically. We observed that AF was generally linked to adverse outcomes, including higher rates of ischemic and bleeding events, and an increased risk of mortality compared to patients without AF. Importantly, while magnesium treatment is commonly included among management strategies, evidence from our study did not support a clear advantage.
Overall, the variations in diagnostic and treatment approaches for AF in different ICUs call attention to the need for standardized care practices. Despite the use of magnesium alongside other interventions, it remains unclear how effective it is for improving patient outcomes in AF cases.
While magnesium was administered to 16% of patients with AF, the results did not indicate significant benefits tied to its use specifically. We observed that AF was generally linked to adverse outcomes, including higher rates of ischemic and bleeding events, and an increased risk of mortality compared to patients without AF. Importantly, while magnesium treatment is commonly included among management strategies, evidence from our study did not support a clear advantage.
Overall, the variations in diagnostic and treatment approaches for AF in different ICUs call attention to the need for standardized care practices. Despite the use of magnesium alongside other interventions, it remains unclear how effective it is for improving patient outcomes in AF cases.
8
We explored the effects of magnesium treatment in patients with atrial fibrillation (AF) undergoing cardioversion with ibutilide. In our study, patients were carefully monitored; those with low magnesium levels received magnesium sulfate before ibutilide was administered.
The results showed that magnesium pretreatment improved patients' chances of converting back to a normal heart rhythm. Specifically, those who received magnesium saw a 70% success rate in returning to normal sinus rhythm (NSR).
We also noticed a significant gender difference in conversion rates—female patients converted to NSR at an impressive rate of 88%, compared to just 68% for males. This finding was interesting and may suggest that factors beyond magnesium alone contribute to treatment success in AF.
The results showed that magnesium pretreatment improved patients' chances of converting back to a normal heart rhythm. Specifically, those who received magnesium saw a 70% success rate in returning to normal sinus rhythm (NSR).
We also noticed a significant gender difference in conversion rates—female patients converted to NSR at an impressive rate of 88%, compared to just 68% for males. This finding was interesting and may suggest that factors beyond magnesium alone contribute to treatment success in AF.
2
We explored the potential of magnesium treatment in preventing new-onset atrial fibrillation (AF) outside of cardiac surgery. A rigorous examination was conducted, analyzing data from several studies that compared magnesium supplementation to a placebo.
Our investigation included five randomized controlled trials, comprising a total of 4,713 participants. After thorough scrutiny, we found that magnesium administration did not significantly lower the occurrence of new-onset AF when compared to placebo treatments.
Despite being a common concern in intensive care, especially given its association with increased health risks, the use of magnesium in this context appears to have no significant effect. Moreover, the studies we reviewed exhibited a variety of biases, adding complexity to our findings.
In conclusion, while magnesium might hold promise in specific patient groups, further research is essential to determine its true efficacy in preventing AF among those who are not undergoing cardiac surgery.
Our investigation included five randomized controlled trials, comprising a total of 4,713 participants. After thorough scrutiny, we found that magnesium administration did not significantly lower the occurrence of new-onset AF when compared to placebo treatments.
Despite being a common concern in intensive care, especially given its association with increased health risks, the use of magnesium in this context appears to have no significant effect. Moreover, the studies we reviewed exhibited a variety of biases, adding complexity to our findings.
In conclusion, while magnesium might hold promise in specific patient groups, further research is essential to determine its true efficacy in preventing AF among those who are not undergoing cardiac surgery.
References
- Meerman M, Buijser M, van den Berg L, van den Heuvel AM, Hoohenkerk G, et al. Magnesium sulphate to prevent perioperative atrial fibrillation in cardiac surgery: a randomized clinical trial : A protocol description of the PeriOperative Magnesium Infusion to Prevent Atrial fibrillation Evaluated (POMPAE) trial. Trials. 2024;25:540. doi:10.1186/s13063-024-08368-3
- Kukendrarajah K, Ahmad M, Carrington M, Ioannou A, Taylor J, et al. External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis. Cochrane Database Syst Rev. 2024;6:CD013255. doi:10.1002/14651858.CD013255.pub2
- Lacki A, Martinez-Millana A. A Comparison of the Impact of Pharmacological Treatments on Cardioversion, Rate Control, and Mortality in Data-Driven Atrial Fibrillation Phenotypes in Critical Care. Bioengineering (Basel). 2024;11. doi:10.3390/bioengineering11030199
- Toida T, Kurita N, Abe M, Hanafusa N, Joki N. Impact of Dysmagnesemia on Atrial Fibrillation in Maintenance Hemodialysis Patients: A Nationwide Study. Cardiorenal Med. 2024;14:105. doi:10.1159/000536595
- Malkoc A, Phan A, Falatoonzadeh P, Mac O, Sherman W, et al. Gender Differences With Ibutilide Effectiveness and Safety in Cardioversion of Atrial Fibrillation. J Surg Res. 2024;296:10. doi:10.1016/j.jss.2023.12.002
- Jin S, An L, Chen L, Liu H, Chen H, et al. Prevention of new-onset atrial fibrillation in elderly patients undergoing anatomic pulmonary resection by infusion of magnesium sulfate: protocol for a randomized controlled trial. Front Cardiovasc Med. 2023;10:1171713. doi:10.3389/fcvm.2023.1171713
- Curran J, Ross-White A, Sibley S. Magnesium prophylaxis of new-onset atrial fibrillation: A systematic review and meta-analysis. PLoS One. 2023;18:e0292974. doi:10.1371/journal.pone.0292974
- Ghezel-Ahmadi V, Ghezel-Ahmadi D, Beck G, Bölükbas S. Perioperative systemic magnesium sulfate minimizes the incidence of atrial fibrillation after thoracotomy for lung resection: a prospective observational study. J Thorac Dis. 2023;15:4648. doi:10.21037/jtd-23-506
- Tempe DK, Maheshwari A, Fatima N, Khurana P, Geelani MA, et al. Role of magnesium alone or in combination with diltiazem and/or amiodarone in prevention of atrial fibrillation following off-pump coronary artery bypass grafting. Ann Card Anaesth. 2023;26:399. doi:10.4103/aca.aca_35_23
- Jadhav JA, Mankhair S, Chakole V. Comparative Evaluation of Dexmedetomidine and Magnesium Sulfate for Prevention of Postoperative Atrial Fibrillation in Patients of Coronary Artery Bypass Surgeries. Cureus. 2023;15:e41075. doi:10.7759/cureus.41075
- Enayati A, Gin JH, Sajeev JK, Cooke JC, Carey P, et al. Efficacy of intravenous magnesium for the management of non-post operative atrial fibrillation with rapid ventricular response: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2023;34:1286. doi:10.1111/jce.15911
- Wetterslev M, Hylander Møller M, Granholm A, Hassager C, Haase N, et al. Atrial Fibrillation (AFIB) in the ICU: Incidence, Risk Factors, and Outcomes: The International AFIB-ICU Cohort Study. Crit Care Med. 2023;51:1124. doi:10.1097/CCM.0000000000005883
- Li L, Lutsey PL, Chen LY, Soliman EZ, Rooney MR, et al. Circulating Magnesium and Risk of Major Adverse Cardiac Events among Patients with Atrial Fibrillation in the ARIC Cohort. Nutrients. 2023;15. doi:10.3390/nu15051211
- Ergün B, Ergan B, Küçük M, Yakar MN, Öztürk MC, et al. Is serum magnesium level associated with atrial fibrillation in the mixed medical/surgical intensive care unit setting?. Magnes Res. 2022;35:96. doi:10.1684/mrh.2023.0506
- Bouillon-Minois JB, Khaled L, Vitte F, Miraillet L, Eschalier R, et al. Ionized Magnesium: Interpretation and Interest in Atrial Fibrillation. Nutrients. 2023;15. doi:10.3390/nu15010236
- Wilson MG, Rashan A, Klapaukh R, Asselbergs FW, Harris SK. Clinician preference instrumental variable analysis of the effectiveness of magnesium supplementation for atrial fibrillation prophylaxis in critical care. Sci Rep. 2022;12:17433. doi:10.1038/s41598-022-21286-1
